There’s no denying that GLP-1 medications like Ozempic and Wegovy are having a moment. You’ve probably seen the headlines, ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

They call this process peptide painting, and it involves GLP-1 receptor agonists. GLP-1s work by improving certain biological ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet ...

After all, the appetite for the medicines is enormous. A J.P. Morgan report estimates that the global market for glucagon-like peptide 1 (GLP-1) drugs could surpass $100 billion by 2030.

Novo Nordisk says an oral drug which can help type 2 diabetes patients to lower their blood sugar, substantially lower their risk of having a heart attack or stroke, and help them lose weight ...

nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of graft loss. For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists ...

Here are five questions answered about the FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed compounding pharmacies must immediately stop making most compound ...